The U.S. Department of Health and Human Services is appealing Monday's ruling that affects how much hospitals pay for drugs ...

By Patrick Demmer As a pastor and community advocate in Colorado, I have spent more than four decades walking alongside ...

Following Eli Lilly and Johnson & Johnson, Sanofi is aiming to change how it participates in the 340B program, a federal drug pricing program created in 1992, The Wall Street Journal reported Nov. 22.

Michigan hospitals are systematically exploiting a program for low-income patients, according to a new report.

Healthcare policy changes may increase uncompensated care, stressing hospitals and the 340B program, crucial for subsidizing low-income patient care. The 340B rebate model, starting in 2026, could ...

The federal 340B Drug Pricing Program, which requires pharmaceutical manufacturers participating in Medicaid to sell outpatient drugs at discounted prices to healthcare organizations that care for ...

In Washington, D.C., lawmakers are engaged in marathon talks about how to reduce health care costs. There haven’t been any ...

As we look ahead to 2026, the operational demands on 340B programs are increasing across every dimension. Between the implementation of the 340B ...

The 340B Drug Discount Program was designed to help safety-net providers make drugs available to low-income patients and earn revenue. Drug manufacturers have put restrictions on which pharmacies ...

The 340B program is criticized for generating revenue rather than solely aiding underinsured patients, impacting community providers and Medicare patients. Pharmaceutical companies face challenges ...

As the Trump administration prepares to force its Most Favored Nation price controls on drug makers, a major U.S. lobbying group is pushing for a change to drug discounts law that would necessitate a ...